Johnson & Johnson Stock Drops 2.3%, Faces $65M Antitrust Settlement
Johnson & Johnson shares fell 2.31%, closing at $239.63 after a monthly gain of 4.62% outpacing the Medical sector, with Q1 EPS forecast at $2.68 (–3.25% YoY) on $23.43B revenue (+7.04%) and full-year EPS of $11.54 on $100.29B revenue. Two J&J units will pay $65M to settle Tracleer antitrust claims.
1. Recent Share Movement and Earnings Projections
JNJ closed at $239.63, down 2.31% from the prior session and underperformed the S&P 500’s 0.57% drop. Shares have risen 4.62% over the past month versus the Medical sector’s 0.06%. Q1 EPS projections stand at $2.68 (–3.25% YoY) on $23.43B revenue (+7.04%), with full-year EPS of $11.54 on $100.29B revenue (+6.47%).
2. Valuation Metrics
The stock trades at a forward P/E of 21.26, a premium to the Large Cap Pharmaceuticals average of 16.25, and carries a PEG ratio of 2.42 versus 2.31 for peers. This positions the company in the bottom 32% of industry rankings.
3. Antitrust Settlement
Two Johnson & Johnson units have agreed to pay $65M to resolve a class action alleging overcharges on the pulmonary hypertension treatment Tracleer, eliminating a legal overhang.